Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β2-agonists in Patients with Moderate to Severe Asthma: A Randomized, Controlled Study

被引:3
|
作者
Wang, Yan [1 ]
Chen, Ping [2 ]
Dai, Anna [1 ]
Shang, Shengyun [1 ]
Kong, Lingfei [1 ]
机构
[1] China Med Univ, Hosp 1, Inst Resp Dis, 155 Nanjing North St, Shenyang 110001, Liaoning Provin, Peoples R China
[2] Gen Hosp Shenyang Mil Reg, Resp Med, Shenyang, Liaoning, Peoples R China
关键词
fluticasone aerosol; moderate to severe persistent asthma; salmeterol/fluticasone propionate aerosol; theophylline tablets; treatment; PERSISTENT ASTHMA; LUNG-FUNCTION; BUDESONIDE; THERAPY; MONTELUKAST;
D O I
10.1016/j.clinthera.2016.10.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To evaluate and contrast the therapeutic effect and safety of fluticasone aerosol combined with theophylline tablets in patients with moderate to severe asthma, compared with salmeterol/fluticasone propionate aerosol. Methods: After a screening period, patients meeting the inclusion criteria were randomly assigned to the experiment group (fluticasone aerosol combined with theophylline tablets) or the control group (salmeterol/ fluticasone aerosol combined with placebo tablets) for 12 weeks of treatment. The main outcome measurements were forced expiratory volume in 1 second and fractional concentration of exhaled nitric oxide value, whereas the secondary measures were forced vital capacity, peak expiratory flow value, and Asthma Control Test/Asthma Quality of Life Questionnaire score. Findings: Forty-four cases completed the course, with 23 cases in the experiment group and 21 cases in the control group. The forced expiratory volume in 1 second values of both groups were significantly improved from before (P < 0.05). The fractional concentration of exhaled nitric oxide values of both groups were significantly decreased from before (P < 0.05). The secondary outcome measurements after treatment achieved obvious improvement from baseline (P < 0.05) in both. There was no significant difference between the 2 groups in all measurements. In addition, the blood biochemistry results, ECG results, and vital signs of both groups had no significant abnormality. Implications: There was no significant difference in therapeutic effect and safety between the 2 groups in treating patients with moderate to severe persistent asthma, which suggests that fluticasone aerosol combined with theophylline tablets is worth considering for use in primary hospitals or for low-income populations. (C) 2016 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:2622 / 2627
页数:6
相关论文
共 50 条
  • [21] Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics
    Caminati, Marco
    Vianello, Andrea
    Andretta, Margherita
    Menti, Anna Michela
    Tognella, Silvia
    Esposti, Luca Degli
    Micheletto, Claudio
    Bovo, Chiara
    Senna, Gianenrico
    ERJ OPEN RESEARCH, 2020, 6 (02)
  • [22] Inhaled combination therapy with long-acting β2-agonists and corticosteroids in stable COPD
    Cazzola, M
    Dahl, R
    CHEST, 2004, 126 (01) : 220 - 237
  • [23] Use of long-acting β-agonists and inhaled corticosteroids
    Glassroth, Jeffrey
    ANNALS OF INTERNAL MEDICINE, 2006, 145 (09) : 710 - 710
  • [24] Long-Acting β-Agonists (LABA) Combined With Long-Acting Muscarinic Antagonists or LABA Combined With Inhaled Corticosteroids for Patients With Stable COPD
    Horita, Nobuyuki
    Nagashima, Akimichi
    Kaneko, Takeshi
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (13): : 1274 - 1275
  • [25] Excess mortality in patients with asthma on long-acting β2-agonists
    Hasford, J.
    Virchow, J. C.
    EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (05) : 900 - 902
  • [26] Asthma control in adult patients treated with a combination of inhaled corticosteroids and long-acting β2-agonists: a prospective observational study
    Rogala, Barbara
    Majak, Pawel
    Gluck, Joanna
    Debowski, Tomasz
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2017, 127 (02): : 100 - 106
  • [27] Long-acting β2-agonists in asthma:: safety concerns
    Wooltorton, E
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (09) : 1030 - 1031
  • [28] Long-acting β2-agonists in asthma -: Not so SMART?
    Currie, Graeme P.
    Lee, Daniel K. C.
    Lipworth, Brian J.
    DRUG SAFETY, 2006, 29 (08) : 647 - 656
  • [29] Increasing Doses of Inhaled Corticosteroids Compared to Adding Long-Acting Inhaled β2-Agonists in Achieving Asthma Control
    O'Byrne, Paul M.
    Naya, Ian P.
    Kallen, Anders
    Postma, Dirkje S.
    Barnes, Peter J.
    CHEST, 2008, 134 (06) : 1192 - 1199
  • [30] Is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma?
    Townsend, Laurie
    Madlon-Kay, Diane J.
    JOURNAL OF FAMILY PRACTICE, 2015, 64 (06): : 370 - 371